Emo Capital Corp (OTCBB:NUVI) Slumps After Male Enhancement Pills Pump
Emo Capital Corp (OTCBB:NUVI) has had a steady couple of months after the decline their stock suffered Aug. to Sept. 2013. Since then the prices of their shares has fluctuated a few times, the most significant occasion being Nov. 21. It rose to $0.021 within the day, only to drop back to $0.012 – exactly where it started – on the very next day.
Dec. 11 saw the next sudden rise of the stock of NUVI, with trading activity unparalleled in recent months (341 trades). Share prices went as high as $0.0399 – an enormous leap, considering that the company’s stock was stuck at three times less that amount for months now. The session closed at a price of $0.021 per share, much like it did the last time it showed any significant trade activity.
The reason for this jump can easily be attributed to NUVI‘s announcement of their new product and the subsequent stock pumps. The so called “RED XL” is an alleged “revolutionary” new type of male enhancement pill of their own design. The drug was actively promoted as having incredible effects. The news quickly got traders excited, as such bold announcements often tend to, but by the end of the day the hype was over. People realized that, although investment in such key niches of the market may be tremendously tempting, “finalization of key ingredients” does not necessarily bring Emo Capital Corp that much closer to bringing a finished, and more importantly – clinically tested – product on the market.
It should also be noted that the company is far from financially sound. It declared the staggering total of $0 in cash and assets, $33,850 in total current liabilities and a $1,084 net loss. Although the figures don’t add to much, low as they are, it is obvious that the financial state of NUVI is not very likely to improve drastically any time soon. The main reason for that appears to be that they just don’t seem to have any income from revenues – they have been around for 2 years and have yet to make a single dollar. Even keeping in mind that ventures based on extensive scientific research take a significant amount of time and effort to bear fruit, their achievements are less than impressive.
And while on the topic of medical and pharmaceutical groundwork, the company listed its total expenses in the 10K they filed on July 31 as $5,554. Which is, needless to say, a suspiciously meager amount of cash to spend on any kind of proper scientific research, let alone pharmaceutical such.
With these facts in mind, it is no surprise that on the very next day after it began to soar, the company’s stock plummeted back to, then even further down than, their original price. On Dec. 11 NUVI closed at $0.009, 52% down.
